Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection-Reference-Cited by-同舟云学术

Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

Published:2022-07-29 Issue:8 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Martinez Mario A¹,Chen Ting-Yi²,Choi Hosoon³,Hwang Munok³,Navarathna Dhammika⁴,Hao Linhue⁵,Gale Michael⁵,Camus Gregory⁶,Ramirez Hector E¹,Jinadatha Chetan²^ORCID

Affiliation:

1. Division of Infectious Diseases, Baylor Scott and White Health , Temple, Texas , USA

2. Department of Medicine, Central Texas Veterans Health Care System , Temple, Texas , USA

3. Department of Research, Central Texas Veterans Health Care System , Temple, Texas , USA

4. Department of Microbiology and Pathology, Central Texas Veterans Health Care System , Temple, Texas , USA

5. Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington , Seattle, Washington , USA

6. Gilead Sciences, Inc , Foster City, California , USA

Abstract

Abstract Persistent severe acute respiratory syndrome coronavirus 2 infection is difficult to treat. Here, we report a case of 5-month persistent coronavirus disease 2019 in an immunocompromised patient who was successfully treated with 30 consecutive days of remdesivir. Prolonged remdesivir infusion with concurrent cycle threshold monitoring might provide a potential solution to cure these patients with difficult-to-treat infections.

Funder

VASeqCURE

American Rescue Plan

Central Texas Veterans Health Care System

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac382/45189708/ofac382.pdf

Reference9 articles.